Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
NOXOPHARM LIMITED (NOX)ASX AI Signals has generated 2 signal(s) for NOX during the last 90 days, indicating Moderate trading activity
Latest NOX Signals | |
| 25/06/2026 | BUY |
| 27/05/2026 | BUY |
NOX Share Price | |
| Current Price | $0.092 |
| 52 Week High | $0.125 |
| 52 Week Low: | $0.044 |
| Trading at (% of 52 Week High) | 73.60% |
Noxopharm Limited (ASX: NOX) is an Australian clinical-stage drug development company focused on creating new cancer treatments. The company specializes in small molecule drugs designed to enhance the effectiveness of immunotherapy and reduce the side effects of chemotherapy.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The BUY signal for NOXOPHARM LIMITED is supported by positive AI-driven indicators, but the relatively low stock price and sector volatility suggest moderate caution. The confidence level reflects balanced potential upside against inherent risks.
The Australian stock market showed mixed performance recently, with utilities and energy sectors leading gains while financials lagged behind. In this fluctuating landscape, investors may find opportunities in penny stocks—an investment area that, despite being somewhat outdated as a term, remains r Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss ma Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But the harsh reality If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But the last three years have been particularly tough on longer term Noxopharm Limited (ASX:NOX) shareholders. So they might be feeling emotional about the 56% share price collapse, in SYDNEY, March 29, 2022--(BUSINESS WIRE)--Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda®, its lead oncology drug candidate, for use in the treatment of soft tissue sarcoma.
The ODD program wasLatest NOXOPHARM LIMITED(NOX) News
3 ASX Penny Stocks With Market Caps Under A$400M To Watch
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Will Noxopharm (ASX:NOX) Spend Its Cash Wisely?
Noxopharm (ASX:NOX) shareholders have endured a 51% loss from investing in the stock three years ago
FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial